341 related articles for article (PubMed ID: 23604103)
21. NK Cell-Mediated Antitumor Effects of a Folate-Conjugated Immunoglobulin Are Enhanced by Cytokines.
Jaime-Ramirez AC; McMichael E; Kondadasula S; Skinner CC; Mundy-Bosse BL; Luedke E; Jones NB; Mani A; Roda J; Karpa V; Li H; Li J; Elavazhagan S; La Perle KM; Schmitt AC; Lu Y; Zhang X; Pan X; Mao H; Davis M; Jarjoura D; Butchar JP; Poi M; Phelps M; Tridandapani S; Byrd JC; Caligiuri MA; Lee RJ; Carson WE
Cancer Immunol Res; 2016 Apr; 4(4):323-336. PubMed ID: 26865456
[TBL] [Abstract][Full Text] [Related]
22. IL-12 directs further maturation of ex vivo differentiated NK cells with improved therapeutic potential.
Lehmann D; Spanholtz J; Sturtzel C; Tordoir M; Schlechta B; Groenewegen D; Hofer E
PLoS One; 2014; 9(1):e87131. PubMed ID: 24498025
[TBL] [Abstract][Full Text] [Related]
23. Blocking NK cell inhibitory self-recognition promotes antibody-dependent cellular cytotoxicity in a model of anti-lymphoma therapy.
Binyamin L; Alpaugh RK; Hughes TL; Lutz CT; Campbell KS; Weiner LM
J Immunol; 2008 May; 180(9):6392-401. PubMed ID: 18424763
[TBL] [Abstract][Full Text] [Related]
24. Systemic and Intra-Nodal Activation of NK Cells After Rituximab Monotherapy for Follicular Lymphoma.
Enqvist M; Jacobs B; Junlén HR; Schaffer M; Melén CM; Friberg D; Wahlin BE; Malmberg KJ
Front Immunol; 2019; 10():2085. PubMed ID: 31572357
[TBL] [Abstract][Full Text] [Related]
25. The human natural killer cytotoxic cell line NK-92, once armed with a murine CD16 receptor, represents a convenient cellular tool for the screening of mouse mAbs according to their ADCC potential.
Clémenceau B; Vivien R; Pellat C; Foss M; Thibault G; Vié H
MAbs; 2013; 5(4):587-94. PubMed ID: 23770975
[TBL] [Abstract][Full Text] [Related]
26. Simultaneous exposure to FcγR and FcαR on monocytes and macrophages enhances antitumor activity in vivo.
Li B; Xu L; Tao F; Xie K; Wu Z; Li Y; Li J; Chen K; Pi C; Mendelsohn A; Larrick JW; Gu H; Fang J
Oncotarget; 2017 Jun; 8(24):39356-39366. PubMed ID: 28454118
[TBL] [Abstract][Full Text] [Related]
27. Anti-CD20 monoclonal antibody with enhanced affinity for CD16 activates NK cells at lower concentrations and more effectively than rituximab.
Bowles JA; Wang SY; Link BK; Allan B; Beuerlein G; Campbell MA; Marquis D; Ondek B; Wooldridge JE; Smith BJ; Breitmeyer JB; Weiner GJ
Blood; 2006 Oct; 108(8):2648-54. PubMed ID: 16825493
[TBL] [Abstract][Full Text] [Related]
28. Anti-CD20 rituximab IgG1, IgG3, and IgG4 but not IgG2 subclass trigger Ca
Freitas Monteiro M; Papaserafeim M; Réal A; Puga Yung GL; Seebach JD
J Leukoc Biol; 2020 Oct; 108(4):1409-1423. PubMed ID: 32620047
[TBL] [Abstract][Full Text] [Related]
29. CD16 pre-ligation by defucosylated tumor-targeting mAb sensitizes human NK cells to γ
Capuano C; Pighi C; Maggio R; Battella S; Morrone S; Palmieri G; Santoni A; Klein C; Galandrini R
Cancer Immunol Immunother; 2020 Apr; 69(4):501-512. PubMed ID: 31950225
[TBL] [Abstract][Full Text] [Related]
30. Fc-optimized NKG2D-Fc constructs induce NK cell antibody-dependent cellular cytotoxicity against breast cancer cells independently of HER2/neu expression status.
Raab S; Steinbacher J; Schmiedel BJ; Kousis PC; Steinle A; Jung G; Grosse-Hovest L; Salih HR
J Immunol; 2014 Oct; 193(8):4261-72. PubMed ID: 25217158
[TBL] [Abstract][Full Text] [Related]
31. Recombinant interleukin-2 significantly augments activity of rituximab in human tumor xenograft models of B-cell non-Hodgkin lymphoma.
Lopes de Menezes DE; Denis-Mize K; Tang Y; Ye H; Kunich JC; Garrett EN; Peng J; Cousens LS; Gelb AB; Heise C; Wilson SE; Jallal B; Aukerman SL
J Immunother; 2007 Jan; 30(1):64-74. PubMed ID: 17198084
[TBL] [Abstract][Full Text] [Related]
32. Antibody Afucosylation Augments CD16-Mediated Serial Killing and IFNγ Secretion by Human Natural Killer Cells.
Karampatzakis A; Brož P; Rey C; Önfelt B; Cruz De Matos GDS; Rycroft D; Ambrose A; Davis DM
Front Immunol; 2021; 12():641521. PubMed ID: 33796107
[TBL] [Abstract][Full Text] [Related]
33. Role of interleukin-2 and interferon-gamma in induction of activated natural killer cells from mice primed in vivo and subsequently challenged in vitro with the streptococcal preparation OK432.
Yamaue H; Tanimura H; Iwahashi M; Tani M; Tsunoda T; Tabuse K; Kuribayashi K; Saito K
Cancer Immunol Immunother; 1989; 29(2):79-86. PubMed ID: 2497980
[TBL] [Abstract][Full Text] [Related]
34. Inhibitors of SRC kinases impair antitumor activity of anti-CD20 monoclonal antibodies.
Winiarska M; Bojarczuk K; Pyrzynska B; Bil J; Siernicka M; Dwojak M; Bobrowicz M; Miazek N; Zapala P; Zagozdzon A; Krol M; Syta A; Podszywalow-Bartnicka P; Pilch Z; Dabrowska-Iwanicka A; Juszczynski P; Efremov DG; Slabicki M; Zenz T; Le Roy A; Olive D; Rygiel TP; Leusen JH; Golab J
MAbs; 2014; 6(5):1300-13. PubMed ID: 25517315
[TBL] [Abstract][Full Text] [Related]
35. A Tridimensional Model for NK Cell-Mediated ADCC of Follicular Lymphoma.
Decaup E; Rossi C; Gravelle P; Laurent C; Bordenave J; Tosolini M; Tourette A; Perrial E; Dumontet C; Poupot M; Klein C; Savina A; Fournié JJ; Bezombes C
Front Immunol; 2019; 10():1943. PubMed ID: 31475004
[TBL] [Abstract][Full Text] [Related]
36. Anti-CD20 Therapy Acts via FcγRIIIA to Diminish Responsiveness of Human Natural Killer Cells.
Capuano C; Romanelli M; Pighi C; Cimino G; Rago A; Molfetta R; Paolini R; Santoni A; Galandrini R
Cancer Res; 2015 Oct; 75(19):4097-108. PubMed ID: 26229120
[TBL] [Abstract][Full Text] [Related]
37. Matrix metalloproteinases inhibition promotes the polyfunctionality of human natural killer cells in therapeutic antibody-based anti-tumour immunotherapy.
Zhou Q; Gil-Krzewska A; Peruzzi G; Borrego F
Clin Exp Immunol; 2013 Jul; 173(1):131-9. PubMed ID: 23607800
[TBL] [Abstract][Full Text] [Related]
38. CpG-A and B oligodeoxynucleotides enhance the efficacy of antibody therapy by activating different effector cell populations.
van Ojik HH; Bevaart L; Dahle CE; Bakker A; Jansen MJ; van Vugt MJ; van de Winkel JG; Weiner GJ
Cancer Res; 2003 Sep; 63(17):5595-600. PubMed ID: 14500400
[TBL] [Abstract][Full Text] [Related]
39. CD24 targeting bi-specific antibody that simultaneously stimulates NKG2D enhances the efficacy of cancer immunotherapy.
Han Y; Sun F; Zhang X; Wang T; Jiang J; Cai J; Gao Q; Hezam K; Liu Y; Xie J; Wang M; Zhang J
J Cancer Res Clin Oncol; 2019 May; 145(5):1179-1190. PubMed ID: 30778749
[TBL] [Abstract][Full Text] [Related]
40. Role of CD16 (Fc receptor III) and interleukin-2 in the reactivation of natural killer cells after inhibitory target cell contact.
Heiskala M; Ståhls A; Seppälä I; Timonen T
Nat Immun Cell Growth Regul; 1991; 10(5):265-77. PubMed ID: 1836835
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
